Module

Timing and Choice of First-Line Antiretroviral Therapy

Source: HIV/AIDS Annual Update 2009

Timing and Choice of First-Line Antiretroviral Therapy

Program Chair: W. David Hardy, MD

Faculty:

Joel E. Gallant, MD, MPH

CREDIT INFORMATION

Release Date: May 27, 2009

Expiration Date: May 26, 2010

Physicians: maximum of 1.0 AMA PRA Category 1 Credit™

Registered Nurses: 1.0 Nursing contact hour

Pharmacists: 1.0 contact hour (0.1 CEUs)

Status: The activity is not currently available for credit.

Learning Objectives

Upon completion of this activity, participants should be able to:

Discuss the rationale for earlier vs later initiation of antiretroviral therapy
Contrast the currently recommended first-line antiretroviral regimens
Describe recommendations on treating special patient populations
Interpret data on the use of newer agents in treatment-naive patients

Topics covered include:

Determining the Optimal Time to Initiate Antiretroviral Therapy
Determining the Optimal Antiretroviral Regimen for First-line Therapy
Ritonavir-Boosted PI Plus 2 NRTIs
NNRTI Plus 2 NRTIs
Unboosted PI Plus 2 NRTIs
Choice of NRTIs for First-Line Therapy
Role of Integrase Inhibitors and CCR5 Antagonists in Treatment-Naive Patients
Choice of Initial Antiretroviral Therapy in Special Populations of HIV-Infected Patients
Author’s Perspective on Current Issues in First-line Therapy

Abstract

Click here to view abstract

Disclaimer: The materials published on the Clinical Care Options Sites reflect the views of the reviewers or authors of the CCO material, not those of Clinical Care Options, LLC, the CME provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.